Dronedarone tablets USP, 400 mg have an estimated market size of US $ 500 million for twelve months ending September 2021 according to IQVIA
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
The drug is priced at Rs 2000 for a course of 40 tablets
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Subscribe To Our Newsletter & Stay Updated
